---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-035074"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:43:48.461122+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# enGene raises $200M via oversubscribed private placement; CEO Hanson to resign for family/health reasons

## Summary
- Sold 20M shares at $10.00 each (31% premium to Feb 13 close); gross proceeds $200M; expected close Feb 16.
- New and existing investors participated, including Adage, Blue Owl, Boxer, Cormorant, Deerfield, and Janus Henderson.
- Proceeds to fund EG-70 pivotal study for BCG-unresponsive NMIBC; cash runway extends into 2027.
- CEO Jason Hanson to resign upon successor appointment due to personal family/health reasons; Board initiated search.
- Hanson will serve as Senior Strategic Advisor for at least six months post-resignation at $25,000/month.

## SEC filing metadata
- accession: 0001193125-24-035074
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312524035074/0001193125-24-035074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312524035074/d772510d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-035074
- JSON: https://secwatch.observer/filing/0001193125-24-035074.json
- Plain text: https://secwatch.observer/filing/0001193125-24-035074.txt

## Key facts
- Executive change
  Jason Hanson departed as Chief Executive Officer at enGene Therapeutics Inc..
  - Action: resign
  - Role: Chief Executive Officer
  source text: Mr. Hanson will resign from his positions as Chief Executive Officer of the Company and as a member of the Company’s Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312524035074/0001193125-24-035074-index.htm
- Material Agreements
  enGene Therapeutics Inc. entered into Subscription Agreements with the investors named therein valued at approximately $200 million (effective 2024-02-13).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the investors named therein
  - Value: approximately $200 million
  - Effective: 2024-02-13
  source text: On February 13, 2024, enGene Holdings Inc. (the “ Company ”) entered into subscription agreements (collectively, the “ Subscription Agreements ”) with the investors named therein (the “ Investors ”), for the private placement (the “ Private Placement ”) of 20,000,000 common shares of the Company (the “ Subscribed Shares ”), at a price of $10.00 per share. The aggregate gross proceeds from the Private Placement are expected to be approximately $200 million, before deducting offering expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312524035074/0001193125-24-035074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.